• All Topics
  • Health Technology Assessment (HTA)
  • Antimicrobial Resistance (AMR)
OHE OHE
Newsletter SignupSubscribe

News & Insights
  • News
  • Events
  • Insights
  • Bulletin
  • News
  • Events
  • Insights
  • Bulletin

News & Insights

  • News
  • Events
  • Insights
  • Bulletin
Newsletter SignupSubscribe
  • News
  • Events
  • Insights
  • Bulletin

Close
OHE OHE
  • Research & Publications
  • News & Insights
  • Education
  • Innovation Policy Prize
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe

Research & Publications

All Publications

Filter by:
  • Antimicrobial Resistance (AMR)
  • Biosimilars
  • Cell and Gene Therapies
  • Chronic Diseases
  • Combination Therapies
  • COVID-19 Research
  • Digital Health
  • Drug Development/R&D
  • Emerging Markets
  • EQ-5D and PROMs
  • Health Care Systems
  • Health Data and Statistics
  • Health Technology Assessment
  • Precision Medicine
  • Real-World Evidence
  • Use of Medicines
  • Value-Based Pricing
  • Vaccine Research
  • Economics of Innovation
  • Measuring and Valuing Outcomes
  • Policy, Organisation and Incentives in Health Systems
  • Value, Affordability and Decision Making

News & Insights

  • News
  • Events
  • Insights
  • Bulletin

Education

  • Education Hub
  • OHE Graduate School
  • EVIA Programme
  • IRA Programme

Innovation Policy Prize

  • The Prize Fund
  • 2022 Prize Fund

Latest Research & Publications

  • Health Technology Assessment…
  • Israel

NICE enough? Do NICE’s Decision Outcomes Impact International HTA Decision-making?

andrew-butler-aUu8tZFNgfM-unsplash
Read more
  • Health Technology Assessment…
  • Value, Affordability, and…
  • Gene therapies

Are Recommendations for HTA of Gene Therapies Being Achieved?

cover 3
Read more
  • Chronic Diseases
  • Value, Affordability, and…
  • Dermatology

The Burden of Hidradenitis Suppurativa on Patients, the NHS and Society

jakob-braun-HfOOKAPsE28-unsplash
Read more
  • Digital Health
  • Economics of Innovation
  • Mental Health

Dementia in the UK: Estimating the Potential Future Impact and Return on Research Investment

image option 1
Read more
  • Precision Medicine
  • Economics of Innovation

The Case for Expanding Uptake of Next-Generation Sequencing for Lung Cancer in Europe

NGS report_AdobeStock_406823942_portrait
Read more
  • Antimicrobial Resistance (AMR)
  • Economics of Innovation

A Novel Incentive Model for Uptake of Diagnostics to Combat Antimicrobial Resistance

Roche AMR diangostics_national-cancer-institute-2fyeLhUeYpg-unsplash_portrait
Read more
  • Health Technology Assessment…
  • Value, Affordability, and…
  • Pricing and Reimbursement

Real-World Evidence: Current Best Practice for Reimbursement Decision-Making

RWE_clay-banks-b5S4FrJb7yQ-unsplash_portrait
Read more
  • Value-Based Pricing
  • Economics of Innovation
  • Pricing and Reimbursement

Delivering the Triple Win: A Value-Based Approach to Pricing

Triple_Win_AdobeStock_249059909_portrait_v2
Read more
Close
OHE
  • All Publications

    Filter by:
    • Antimicrobial Resistance (AMR)
    • Biosimilars
    • Cell and Gene Therapies
    • Chronic Diseases
    • Combination Therapies
    • COVID-19 Research
    • Digital Health
    • Drug Development/R&D
    • Emerging Markets
    • EQ-5D and PROMs
    • Health Care Systems
    • Health Data and Statistics
    • Health Technology Assessment
    • Precision Medicine
    • Real-World Evidence
    • Use of Medicines
    • Value-Based Pricing
    • Vaccine Research
    • Economics of Innovation
    • Measuring and Valuing Outcomes
    • Policy, Organisation and Incentives in Health Systems
    • Value, Affordability and Decision Making
    • News
    • Events
    • Insights
    • Bulletin
    • Education Hub
    • OHE Graduate School
    • EVIA Programme
    • IRA Programme
    • The Prize Fund
    • 2022 Prize Fund
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe
Back
  • News
11 min read 24th April 2012

New Research on VBP: Disease Severity and Unmet Need in the UK

The UK Department of Health’s value based pricing (VBP) Consultation Document proposes a process whereby higher prices would be granted to medicines that tackle diseases that produce the greatest burdens of illness – i.e. those diseases that are most severe…

Share:
  •  Twitter
  •  LinkedIn
  •  Facebook
  • has-icon Email
Koonal Shah

The UK Department of Health’s value based pricing (VBP) Consultation Document proposes a process whereby higher prices would be granted to medicines that tackle diseases that produce the greatest burdens of illness – i.e. those diseases that are most severe or are associated with the greatest unmet need.

Koonal Shah

Koonal Shah

The UK Department of Health’s value based pricing (VBP) Consultation Document proposes a process whereby higher prices would be granted to medicines that tackle diseases that produce the greatest burdens of illness – i.e. those diseases that are most severe or are associated with the greatest unmet need.  This suggests combining severity of disease and unmet need into a single metric.  A literature review reveals that this approach has not been studied adequately (or perhaps at all) to date, either in the UK or elsewhere.

The Department of Health’s Policy Research Unit in Economic Evaluation of Health and Care Interventions (EEPRU) was asked by the Department to conduct an empirical study of society’s resource allocation preferences to obtain weights for burden of illness, therapeutic improvement and end-of-life.  The objective would be to apply these, under the coming VBP system, to assessments of both new technologies and displaced activities.

The EEPRU study defines burden of illness as distance from “normal” health; the measure combines health status with the effects of existing standard therapy on both length and quality of life.  The value of existing therapy, then, is in its contribution to the degree of burden.  Not considered explicitly in the EEPRU study are issues raised by the definition of unmet need implied in the VBP Consultation Document – i.e. that “unmet need” means that no treatment is available at all.

Data collection for the EEPRU study is being conducted online, using discrete choice experiments to elicit preferences.  Stakeholders have expressed concern about the limited scope of the EEPRU study in that it does not examine whether people have preferences about the availability of alternative treatments.

To address some of these issues, OHE currently is performing a small study, funded by an unrestricted research grant from the ABPI.  Based on interviews with members of the general public, it is intended to develop a more nuanced understanding of the extent of societal support for basing health care resource priorities on disease severity and unmet need.

The OHE survey will be administered in face-to-face interviews conducted by trained interviewers with experience in conducting health care preference studies.  Questions will be designed to identify respondents’ levels of support for policies that give greater weight to treatments that address disease severity and unmet medical need than to those that do not.  The research also will address whether, controlling for disease severity, unmet need per se affects societal preferences regarding priorities for treatment.  In this study, respondents also will be asked probing follow-up questions intended to elicit qualitative information about the thinking behind their choices.

This study will provide important, preliminary information about how disease severity and unmet need should be measured and how best to capture societal preferences.  The main points we expect the research to address include the following:

  1. Whether members of the public would support a policy that uses combined disease severity and unmet need as a criterion for priority setting
  2. What societal preferences about disease severity and unmet need can be observed
  3. Whether preferences regarding unmet need depend at least in part on disease severity
  4. The likely reasons for the preferences observed
  5. The strength of the preferences observed

The OHE study, then, will both complement the EEPRU study by exploring additional possible attributes and provide additional evidence about whether preferences regarding unmet need depend on disease severity.  It can help define what further research is essential to produce valid measures.

The OHE research team for the project is Koonal Shah and Nancy Devlin.  Results are anticipated in summer 2012 and will be published as an OHE Research Paper.

  • Value-Based Pricing
  • Value, Affordability, and…
  • Grants

Related News

  • News
  • December 2019

New OHE Research Funding: Improving Labour Productivity in Primary Care

Read more
  • News
  • October 2019

Making Outcome-based Payment a Reality in the NHS: Moving to the Next Phase

Read more
  • News
  • May 2019

OHE is Leading Research to Develop EQ-5D ‘Bolt-ons’ for Cognition and Vision

Read more
  • News
  • September 2018

UKRI Funds OHE Collaboration in Student Mental Health Research Network

Read more
footer_ohe_logo

Leading intellectual authority on global health economics

Sign Up for OHE Insights, Events & News Bulletin

Newsletter SignupStart Sign Up

Research & Publications

News & Insights

Innovation Policy Prize

Education

Events

About Us

OHE Experts

Contact Us

Sign Up for OHE Insights, Events & News Bulletin

Newsletter SignupStart Sign Up

The Office of Health Economics (OHE) is a company limited by guarantee registered in England and Wales (registered number 09848965) and its registered office is at 2nd Floor Goldings House, Hay’s Galleria, 2 Hay’s Lane, London, SE1 2HB.

Terms & Conditions

Privacy Policy

Cookies Policy

© 2023 Website Design

An error has occurred, please try again later.An error has occurred, please try again later.

We are using cookies to give you the best experience on our website.

You can find out more about which cookies we are using or switch them off in .

 Twitter
 Facebook
 LinkedIn
 Copy
 Email
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.

3rd Party Cookies

This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.

Keeping this cookie enabled helps us to improve our website.

Please enable Strictly Necessary Cookies first so that we can save your preferences!